Severe FECD increases risk of glaucoma and OHT

Article

Severe Fuchs endothelial corneal dystrophy (FECD) increases the risk of developing glaucoma and/or ocular hypertension (G/OHT).

Severe Fuchs endothelial corneal dystrophy (FECD) increases the risk of developing glaucoma and/or ocular hypertension (G/OHT).

Dr Mehul Nagarsheth et al., Wills Eye Institute/Jefferson Medical College, Philadelphia, Pennsylvania, USA, studied a subset of 1610 from the FECD Genetics Multi-Centre Study. Logistic regression models, adjusted for age, sex, central corneal thickness, IOP, presence of diabetes and time of day of the initial evaluation, were used.

Of the total eyes included in the study, 107 eyes had G/OHT and the prevalence of G/OHT in the control group was 6%. Eyes with a grade of four through to six were more likely to have concurrent G/OHT than eyes with no record of FECD.

Prevalence of G/OHT was lower in index cases with an FECD grade of one to three and family members with a grade of zero through to three. But it was higher in index cases and family members with a grade of four to six. The logistic regression models demonstrated no correlation between sex, diabetes, time of day of evaluation and central corneal thickness with prevalence of G/OHT.

The abstract can be found in the journal Archives of Ophthalmology.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
© 2025 MJH Life Sciences

All rights reserved.